Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ENDRA Life Sciences (NDRA) EBITDA (2016 - 2021)

Historic EBITDA for ENDRA Life Sciences (NDRA) over the last 6 years, with Q4 2021 value amounting to -$3.1 million.

  • ENDRA Life Sciences' EBITDA fell 3625.0% to -$3.1 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$11.5 million, marking a year-over-year increase of 3.14%. This contributed to the annual value of -$10.8 million for FY2024, which is 281.74% down from last year.
  • Latest data reveals that ENDRA Life Sciences reported EBITDA of -$3.1 million as of Q4 2021, which was down 3625.0% from -$2.7 million recorded in Q3 2021.
  • Over the past 5 years, ENDRA Life Sciences' EBITDA peaked at -$360697.0 during Q1 2017, and registered a low of -$3.3 million during Q3 2020.
  • Moreover, its 5-year median value for EBITDA was -$2.6 million (2019), whereas its average is -$2.4 million.
  • Per our database at Business Quant, ENDRA Life Sciences' EBITDA plummeted by 68670.41% in 2018 and then skyrocketed by 2799.16% in 2020.
  • Quarter analysis of 5 years shows ENDRA Life Sciences' EBITDA stood at -$2.3 million in 2017, then increased by 12.79% to -$2.0 million in 2018, then crashed by 56.31% to -$3.1 million in 2019, then increased by 27.99% to -$2.3 million in 2020, then plummeted by 36.25% to -$3.1 million in 2021.
  • Its EBITDA stands at -$3.1 million for Q4 2021, versus -$2.7 million for Q3 2021 and -$3.2 million for Q2 2021.